Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and MRG-003 in EBV-Associated Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07267338Phase 2Active, not recruiting
- Start
- Feb 2026
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, becotatug vedotin in nasopharyngeal carcinoma (NPC). Started Feb 2026; status: active, not recruiting.
02
Drugs
pembrolizumabbecotatug vedotin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07267338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07267338.